Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | CASP1 | P29466 | 1/20 | 0.57 |
| ▸ | CASP7 | P55210 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14218137 | 0.87 | KDM4E (0.65) | KDM4EPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL1616766 | 0.86 | KMT2A (0.60) | KDM4EPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL4377754 | 0.83 | KDM4E (0.60) | KDM4EPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL5066313 | 0.81 | KMT2A (0.65) | KDM4EPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL13097845 | 0.81 | KDM4E (0.70) | KDM4EPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL10771524 | 0.81 | KDM4E (0.63) | KDM4EPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL4377262 | 0.78 | KMT2A (0.66) | KDM4EPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL4665608 | 0.78 | TSHR (0.47) | POLBKMT2AMEN1TSHR | |
| SCHEMBL4382131 | 0.77 | KMT2A (0.68) | KDM4EPOLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL4377690 | 0.76 | KMT2A (0.72) | KDM4EPOLBKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394835-B2 | Aromatic compounds and their use in medical applications | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-03-12 | — | — | US | disclosed |
| US-8394835-B2 | Aromatic compounds and their use in medical applications | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-03-12 | — | — | US | disclosed |
| US-8394835-B2 | Aromatic compounds and their use in medical applications | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-03-12 | — | — | US | disclosed |
| US-8367677-B2 | Comprising trihydroxy phenyl subunits; selectin inhibitors; side effect reduction; 3-{3-[3-(3,4,5-Trihydroxy-phenyl)-propionylamino]-phenylamino}-benzoic acid | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-02-05 | — | — | US | disclosed |
| US-8367677-B2 | Comprising trihydroxy phenyl subunits; selectin inhibitors; side effect reduction; 3-{3-[3-(3,4,5-Trihydroxy-phenyl)-propionylamino]-phenylamino}-benzoic acid | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-02-05 | — | — | US | disclosed |
| US-8367677-B2 | Comprising trihydroxy phenyl subunits; selectin inhibitors; side effect reduction; 3-{3-[3-(3,4,5-Trihydroxy-phenyl)-propionylamino]-phenylamino}-benzoic acid | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2013-02-05 | — | — | US | disclosed |
| EP-1732882-B1 | NON-GLYCOSYLATED/NON-GLYCOSIDIC/NON-PEPTIDIC SMALL MOLECULE PSGL-1 MIMETICS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2012-07-04 | — | — | EP | disclosed |
| EP-1732882-B1 | NON-GLYCOSYLATED/NON-GLYCOSIDIC/NON-PEPTIDIC SMALL MOLECULE PSGL-1 MIMETICS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2012-07-04 | — | — | EP | disclosed |
| EP-1940372-B1 | NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-11-09 | — | — | EP | disclosed |
| EP-1940372-B1 | NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2011-11-09 | — | — | EP | disclosed |
| US-20080207639-A1 | Novel Aromatic Compounds and Their Use in Medical Applications | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207639-A1 | Novel Aromatic Compounds and Their Use in Medical Applications | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207639-A1 | Novel Aromatic Compounds and Their Use in Medical Applications | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2008-08-28 | — | — | US | disclosed |
| EP-1940372-A1 | NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS | Revotar Biopharmaceuticals AG (DE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007039113-A1 | NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039113-A1 | NOVEL AROMATIC COMPOUNDS AND THEIR USE IN MEDICAL APPLICATIONS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| EP-1764093-A1 | Novel aromatic compounds and their use in medical applications | Revotar Biopharmaceuticals AG (DE) | 2007-03-21 | — | — | EP | disclosed |
| EP-1764093-A1 | Novel aromatic compounds and their use in medical applications | Revotar Biopharmaceuticals AG (DE) | 2007-03-21 | — | — | EP | disclosed |
| EP-1732882-A1 | NON-GLYCOSYLATED/NON-GLYCOSIDIC/NON-PEPTIDIC SMALL MOLECULE PSGL-1 MIMETICS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Revotar Biopharmaceuticals AG (DE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005090284-A1 | NON-GLYCOSYLATED/NON-GLYCOSIDIC/NON-PEPTIDIC SMALL MOLECULE PSGL-1 MIMETICS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207639-A1 | Novel Aromatic Compounds and Their Use in Medical Applications | SELP, SELL, SELE | KDM4E 2771/4885POLB 4081/4885KMT2A 3853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.